metoprolol has been researched along with Pulmonary Disease, Chronic Obstructive in 26 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
Pulmonary Disease, Chronic Obstructive: A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study compared the survival and the risk of heart failure (HF), chronic obstructive pulmonary disease (COPD), diabetes mellitus (DM), hypoglycemia, and renal failure (RF) hospitalizations in geriatric patients exposed to carvedilol or metoprolol." | 7.96 | Metoprolol Versus Carvedilol in Patients With Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes Mellitus, and Renal Failure. ( Andersen, M; Jensen, MT; Kragholm, K; Rasmussen, DB; Sessa, M; Torp-Pedersen, C, 2020) |
| " After adjustment for age, sex, comorbidities, and severity of HF and COPD, bisoprolol use showed a dose-response survival benefit [low dose: adjusted hazard ratio (HR) = 0." | 5.43 | Carvedilol, Bisoprolol, and Metoprolol Use in Patients With Coexistent Heart Failure and Chronic Obstructive Pulmonary Disease. ( Chang, YS; Chen, TJ; Chou, KT; Hu, YW; Hung, MH; Lee, FY; Liu, CJ; Ou, SM; Perng, DW; Su, VY; Yang, KY, 2016) |
| " No adverse event was experienced." | 5.32 | Metoprolol, a beta-1 selective blocker, can be used safely in coronary artery disease patients with chronic obstructive pulmonary disease. ( Akkuş, N; Alkan, M; Arikan, S; Avan, C; Aydoğdu, S; Camsari, A; Ciçek, D; Kaya, D; Kiykim, A; Pekdemir, H; Sezer, K, 2003) |
| "To compare the hazard of all-cause, chronic obstructive pulmonary disease (COPD) and heart failure (HF) hospitalization in carvedilol vs." | 5.27 | Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study. ( Andersen, MP; Capuano, A; Enghusen-Poulsen, H; Gislason, G; Mascolo, A; Mortensen, RN; Rosano, GMC; Rossi, F; Sessa, M; Torp-Pedersen, C, 2018) |
| " A comparative study on the efficacy and safety of bisoprolol and sustained release metoprolol succinate in patients with arterial hypertension (AH), cardiovascular disease (CVD) and chronic obstructive pulmonary disease (COPD) was conducted." | 5.19 | [Efficacy and safety of bisoprololal in hypertensive patients with cardiovascular disease and chronic obstructive pulmonary disease]. ( Chernikov, MV; Derevianchenko, MV; Lopushkova, IuE; Statsenko, ME, 2014) |
| "This study compared the survival and the risk of heart failure (HF), chronic obstructive pulmonary disease (COPD), diabetes mellitus (DM), hypoglycemia, and renal failure (RF) hospitalizations in geriatric patients exposed to carvedilol or metoprolol." | 3.96 | Metoprolol Versus Carvedilol in Patients With Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes Mellitus, and Renal Failure. ( Andersen, M; Jensen, MT; Kragholm, K; Rasmussen, DB; Sessa, M; Torp-Pedersen, C, 2020) |
| "Clinical guidelines suggest that for patients with heart failure and concurrent chronic obstructive pulmonary disease (COPD), metoprolol/bisoprolol/nebivolol should be preferred over carvedilol." | 3.91 | Beta-blocker choice and exchangeability in patients with heart failure and chronic obstructive pulmonary disease: an Italian register-based cohort study. ( Andersen, M; Capuano, A; Jensen, MT; Kragholm, K; Mascolo, A; Pagliaro, C; Rafaniello, C; Rasmussen, DB; Rossi, F; Sessa, M; Sportiello, L; Tari, GM, 2019) |
| "To assess efficacy and safety of selective beta-adrenoblockers (BAB) metoprolol succinate and nebivolol in patients with arterial hypertension (AH) and/or IHD associated with bronchoobstructive syndrome (BOS)." | 3.74 | [Administration of cardioselective beta-adrenoblockers in patients with arterial hypertension and/or ischemic heart disease associated with bronchoobstructive syndrome]. ( Litvinova, IV; Mikolkin, VI; Ovcharenko, SI, 2007) |
| "Pulmonary hypertension (PH) in COPD confers increased risk of exacerbations (ECOPD)." | 3.30 | Association between P-pulmonale and respiratory morbidity in COPD: a secondary analysis of the BLOCK-COPD trial. ( Bittner, V; Dransfield, MT; Helgeson, ES; Kunisaki, KM; Lammi, MR; Ling, SX; MacDonald, DM; Mkorombindo, T; Pew, K; Voelker, H; Wade, RC, 2023) |
| "The Beta-blockeRs tO patieNts with CHronIc Obstructive puLmonary diseasE (BRONCHIOLE) study is an open-label, multicentre, prospective RCT." | 2.94 | Beta-blockeRs tO patieNts with CHronIc Obstructive puLmonary diseasE (BRONCHIOLE) - Study protocol from a randomized controlled trial. ( Andell, P; Fröbert, O; Magnuson, A; Montgomery, S; Rindler, G; Sundh, J, 2020) |
| "Among patients with moderate or severe COPD who did not have an established indication for beta-blocker use, the time until the first COPD exacerbation was similar in the metoprolol group and the placebo group." | 2.90 | Metoprolol for the Prevention of Acute Exacerbations of COPD. ( Bhatt, SP; Brenner, K; Casaburi, R; Come, CE; Connett, JE; Cooper, JAD; Criner, GJ; Curtis, JL; Dransfield, MT; Han, MK; Hatipoğlu, U; Helgeson, ES; Jain, VV; Kalhan, R; Kaminsky, D; Kaner, R; Kunisaki, KM; Lambert, AA; Lammi, MR; Lazarus, SC; Lindberg, S; Make, BJ; Martinez, FJ; McEvoy, C; Panos, RJ; Reed, RM; Scanlon, PD; Sciurba, FC; Smith, A; Sriram, PS; Stringer, WW; Voelker, H; Weingarten, JA; Wells, JM; Westfall, E, 2019) |
| "A substantial majority of chronic obstructive pulmonary disease (COPD)-related morbidity, mortality and healthcare costs are due to acute exacerbations, but existing medications have only a modest effect on reducing their frequency, even when used in combination." | 2.82 | β-Blockers for the prevention of acute exacerbations of chronic obstructive pulmonary disease (βLOCK COPD): a randomised controlled study protocol. ( Bhatt, SP; Connett, JE; Criner, GJ; Dransfield, MT; Lazarus, SC; Lindberg, SM; Voelker, H; Wells, JM; Westfall, E, 2016) |
| "In subjects with COPD, forced expiratory volume in 1 s was lowest with carvedilol and highest with bisoprolol (carvedilol 1." | 2.75 | Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. ( Coleman, CF; Elsik, M; Hayward, CS; Jabbour, A; Keogh, AM; Kotlyar, E; Krum, H; Macdonald, PS; Mellemkjaer, S, 2010) |
| "Within the COPD GOLD II stage group, there appears to be no statistically significant difference in the number of exacerbations between the patients taking verapamil and digoxin (n = 24) and the patients taking BBs alone (n = 15), although, in patients taking BBs alone, there appears to be a trend towards a decrease in the exacerbations compared to the number of exacerbations in patients taking verapamil and digoxin (p = 0." | 1.51 | Beta-blocker Use in Moderate and Severe Chronic Obstructive Pulmonary Disease. ( Bedak, O; Begic, E; Bradaric, H; Custovic, F; Durak-Nalbantic, A; Hodzic, E; Mujakovic, A; Prnjavorac, B; Zvizdic, F, 2019) |
| "To verify the previously reported association between long-term use of β2-adrenoreceptor (β2AR) agonist and antagonist with reduced and increased risk of Parkinson disease (PD), respectively." | 1.51 | Use of β2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease. ( Blaabjerg, M; Christensen, K; Deuschl, G; Höglinger, GU; Hopfner, F; Kuhlenbäumer, G; Pottegård, A; Rösler, TW; Wod, M, 2019) |
| "Bisoprolol was found to reduce mortality and CHF exacerbation compared to carvedilol and metoprolol." | 1.46 | The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study. ( Chen, CY; Huang, YB; Kuo, CC; Liao, KM; Lin, TY, 2017) |
| " After adjustment for age, sex, comorbidities, and severity of HF and COPD, bisoprolol use showed a dose-response survival benefit [low dose: adjusted hazard ratio (HR) = 0." | 1.43 | Carvedilol, Bisoprolol, and Metoprolol Use in Patients With Coexistent Heart Failure and Chronic Obstructive Pulmonary Disease. ( Chang, YS; Chen, TJ; Chou, KT; Hu, YW; Hung, MH; Lee, FY; Liu, CJ; Ou, SM; Perng, DW; Su, VY; Yang, KY, 2016) |
| " No adverse event was experienced." | 1.32 | Metoprolol, a beta-1 selective blocker, can be used safely in coronary artery disease patients with chronic obstructive pulmonary disease. ( Akkuş, N; Alkan, M; Arikan, S; Avan, C; Aydoğdu, S; Camsari, A; Ciçek, D; Kaya, D; Kiykim, A; Pekdemir, H; Sezer, K, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (19.23) | 29.6817 |
| 2010's | 11 (42.31) | 24.3611 |
| 2020's | 10 (38.46) | 2.80 |
| Authors | Studies |
|---|---|
| Parekh, TM | 1 |
| Helgeson, ES | 4 |
| Connett, J | 1 |
| Voelker, H | 4 |
| Ling, SX | 2 |
| Lazarus, SC | 3 |
| Bhatt, SP | 3 |
| MacDonald, DM | 2 |
| Mkorombindo, T | 2 |
| Kunisaki, KM | 3 |
| Fortis, S | 1 |
| Kaminsky, D | 2 |
| Dransfield, MT | 5 |
| Wade, RC | 1 |
| Pew, K | 1 |
| Bittner, V | 1 |
| Lammi, MR | 2 |
| Sessa, M | 3 |
| Mascolo, A | 2 |
| Rasmussen, DB | 2 |
| Kragholm, K | 2 |
| Jensen, MT | 2 |
| Sportiello, L | 1 |
| Rafaniello, C | 1 |
| Tari, GM | 1 |
| Pagliaro, C | 1 |
| Andersen, M | 2 |
| Rossi, F | 2 |
| Capuano, A | 2 |
| Zvizdic, F | 1 |
| Begic, E | 1 |
| Mujakovic, A | 1 |
| Hodzic, E | 1 |
| Prnjavorac, B | 1 |
| Bedak, O | 1 |
| Custovic, F | 1 |
| Bradaric, H | 1 |
| Durak-Nalbantic, A | 1 |
| MacNee, W | 1 |
| Brenner, K | 1 |
| Casaburi, R | 1 |
| Come, CE | 1 |
| Cooper, JAD | 1 |
| Criner, GJ | 2 |
| Curtis, JL | 1 |
| Han, MK | 1 |
| Hatipoğlu, U | 1 |
| Jain, VV | 1 |
| Kalhan, R | 1 |
| Kaner, R | 1 |
| Lambert, AA | 1 |
| Lindberg, S | 1 |
| Make, BJ | 1 |
| Martinez, FJ | 1 |
| McEvoy, C | 1 |
| Panos, RJ | 1 |
| Reed, RM | 1 |
| Scanlon, PD | 1 |
| Sciurba, FC | 1 |
| Smith, A | 1 |
| Sriram, PS | 1 |
| Stringer, WW | 1 |
| Weingarten, JA | 1 |
| Wells, JM | 3 |
| Westfall, E | 2 |
| Connett, JE | 3 |
| Onakpoya, IJ | 1 |
| Sundh, J | 1 |
| Magnuson, A | 1 |
| Montgomery, S | 1 |
| Andell, P | 1 |
| Rindler, G | 1 |
| Fröbert, O | 1 |
| Torp-Pedersen, C | 2 |
| Reese, Z | 1 |
| Ganatra, RB | 1 |
| Doumas, M | 1 |
| Imprialos, KP | 1 |
| Stavropoulos, K | 1 |
| Mehmood, M | 1 |
| Wade, C | 1 |
| Liao, KM | 1 |
| Lin, TY | 1 |
| Huang, YB | 1 |
| Kuo, CC | 1 |
| Chen, CY | 1 |
| Mortensen, RN | 1 |
| Andersen, MP | 1 |
| Rosano, GMC | 1 |
| Gislason, G | 1 |
| Enghusen-Poulsen, H | 1 |
| Hopfner, F | 1 |
| Wod, M | 1 |
| Höglinger, GU | 1 |
| Blaabjerg, M | 1 |
| Rösler, TW | 1 |
| Kuhlenbäumer, G | 1 |
| Christensen, K | 1 |
| Deuschl, G | 1 |
| Pottegård, A | 1 |
| Statsenko, ME | 1 |
| Derevianchenko, MV | 1 |
| Chernikov, MV | 1 |
| Lopushkova, IuE | 1 |
| Su, VY | 1 |
| Chang, YS | 1 |
| Hu, YW | 1 |
| Hung, MH | 1 |
| Ou, SM | 1 |
| Lee, FY | 1 |
| Chou, KT | 1 |
| Yang, KY | 1 |
| Perng, DW | 1 |
| Chen, TJ | 1 |
| Liu, CJ | 1 |
| Lindberg, SM | 1 |
| Cazzola, M | 1 |
| Matera, MG | 1 |
| Jabbour, A | 1 |
| Macdonald, PS | 1 |
| Keogh, AM | 1 |
| Kotlyar, E | 1 |
| Mellemkjaer, S | 1 |
| Coleman, CF | 1 |
| Elsik, M | 1 |
| Krum, H | 1 |
| Hayward, CS | 1 |
| Camsari, A | 1 |
| Arikan, S | 1 |
| Avan, C | 1 |
| Kaya, D | 1 |
| Pekdemir, H | 1 |
| Ciçek, D | 1 |
| Kiykim, A | 1 |
| Sezer, K | 1 |
| Akkuş, N | 1 |
| Alkan, M | 1 |
| Aydoğdu, S | 1 |
| van der Woude, HJ | 1 |
| Zaagsma, J | 1 |
| Postma, DS | 1 |
| Winter, TH | 1 |
| van Hulst, M | 1 |
| Aalbers, R | 1 |
| Ahrens, W | 1 |
| Hagemeier, C | 1 |
| Mühlbauer, B | 1 |
| Pigeot, I | 1 |
| Püntmann, I | 1 |
| Reineke, A | 1 |
| Steinbach, M | 1 |
| Timm, J | 1 |
| Ovcharenko, SI | 1 |
| Litvinova, IV | 1 |
| Mikolkin, VI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Beta-Blockers for the Prevention of Acute Exacerbations of COPD[NCT02587351] | Phase 3 | 532 participants (Actual) | Interventional | 2016-05-01 | Terminated (stopped due to Futility) | ||
| Beta-blockeRs tO patieNts With CHronIc Obstructive puLmonary diseasE[NCT03566667] | Phase 4 | 1,700 participants (Anticipated) | Interventional | 2018-06-12 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
All-cause mortality count (NCT02587351)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Metoprolol Succinate | 11 |
| Placebo | 5 |
COPD Assessment Test (CAT) change from baseline. The CAT is a simple, eight item, health status instrument for patients with COPD that provides a score of 0-40. Lower scores denote better health status. (NCT02587351)
Timeframe: Baseline, 1 year
| Intervention | score on a scale (Mean) |
|---|---|
| Metoprolol Succinate | 0.88 |
| Placebo | -0.59 |
6MWD change from baseline to visit day 336. The 6MWD has been used as a simple tool to assess overall exercise tolerance in patients with chronic cardiopulmonary disease including COPD. (NCT02587351)
Timeframe: Baseline, 1 year
| Intervention | meters (Mean) |
|---|---|
| Metoprolol Succinate | -17.64 |
| Placebo | -11.87 |
Change in FEV1 % Predicted from baseline to visit day 336 as assessed by spirometry (NCT02587351)
Timeframe: 1 year
| Intervention | percentage of predicted (Mean) |
|---|---|
| Metoprolol Succinate | -2.24 |
| Placebo | -1.46 |
Number of hospital days resulting from acute exacerbations of COPD reported as negative binomial estimates of mean hospital days per patient year. (NCT02587351)
Timeframe: 14 months
| Intervention | hospital days (Mean) |
|---|---|
| Metoprolol Succinate | 3.09 |
| Placebo | 0.96 |
Modified Medical Research Council Dyspnea Scale (MMRC) change from baseline to visit day 336. The MMRC scale is a five-point scale originally published in 1959 that considers certain activities, such as walking or climbing stairs, which provoke breathlessness. Scale from 0 to 4 with lower scores indicating less breathlessness. (NCT02587351)
Timeframe: 1 year
| Intervention | score on a scale (Median) |
|---|---|
| Metoprolol Succinate | 2.0 |
| Placebo | 2.0 |
Number of acute exacerbations of COPD - rate per person-year (NCT02587351)
Timeframe: 1 year
| Intervention | no. of events/person-yr (Mean) |
|---|---|
| Metoprolol Succinate | 1.40 |
| Placebo | 1.33 |
Number of Emergency Department visits resulting from acute exacerbations of COPD - rate (NCT02587351)
Timeframe: 1 year
| Intervention | events per person-year (Mean) |
|---|---|
| Metoprolol Succinate | 0.17 |
| Placebo | 0.18 |
Number of hospital admissions resulting from acute exacerbations of COPD - rate (NCT02587351)
Timeframe: 1 year
| Intervention | events per person-year (Mean) |
|---|---|
| Metoprolol Succinate | 0.66 |
| Placebo | 0.42 |
"San Diego Shortness of Breath Questionnaire (SOBQ) change from baseline. A 24-item measure that assesses self-reported shortness of breath while performing a variety of activities of daily living. Each item has a 6-point scale (0 = not at all to 5 = maximal or unable to do because of breathlessness)." (NCT02587351)
Timeframe: 1 year
| Intervention | score on a scale (Mean) |
|---|---|
| Metoprolol Succinate | 0.52 |
| Placebo | -0.25 |
SGRQ change from baseline to visit day 336. The SGRQ total score change from baseline. SGRQ is a respiratory specific health status questionnaire with scores ranging from 0 to 100. The lower score indicates a better health status. (NCT02587351)
Timeframe: Baseline, 1 year
| Intervention | score on a scale (Mean) |
|---|---|
| Metoprolol Succinate | 0.52 |
| Placebo | -0.25 |
"Acute exacerbations are defined as a complex of respiratory symptoms (increase or new onset) of more than one of the following: cough, sputum, wheezing, dyspnea, or chest tightness requiring treatment with antibiotics and/or systemic steroids for at least three days." (NCT02587351)
Timeframe: 1 year
| Intervention | days (Mean) |
|---|---|
| Metoprolol Succinate | 202 |
| Placebo | 222 |
MACE defined by cardiovascular death, hospitalization for myocardial infarction, heart failure, or stroke (NCT02587351)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Myocardial Infarction | Heart Failure | Stroke | Sudden cardiac death | COPD Exacerbation (Serious) | |
| Metoprolol Succinate | 2 | 2 | 1 | 0 | 55 |
| Placebo | 1 | 3 | 1 | 1 | 32 |
New or worsened (Neural: depression, headache, syncope, seizures, somnolence, memory loss, loss of sexual desire or erectile dysfunction, and fatigue; Hypersensitivity: rash, pruritus, tongue or facial swelling; Gastrointestinal: diarrhea, vomiting, nausea or constipation; Cardiovascular: bradycardia and hypotension as discussed below; Respiratory: bronchospasm and changes in lung function as discussed below). (NCT02587351)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Depression | Headache | Fainting | Daytime Sleepiness | Memory Loss | Loss of sexual desire or erectile dysfunction | Lack of energy | Rash | Itching | Tongue or facial swelling | Vomiting | Nausea | Constipation | Wheezing | Shortness of breath | Chest tightness | Heart skipping or irregular beats | Dizziness/light headedness | |
| Metoprolol Succinate | 28 | 71 | 4 | 58 | 20 | 10 | 91 | 17 | 11 | 7 | 11 | 45 | 30 | 88 | 115 | 81 | 16 | 74 |
| Placebo | 39 | 78 | 8 | 70 | 21 | 6 | 77 | 21 | 18 | 5 | 18 | 42 | 32 | 79 | 112 | 80 | 15 | 64 |
Major adverse cardiovascular events (MACE), percutaneous coronary intervention or coronary artery bypass grafting. MACE defined by cardiovascular death, hospitalization for myocardial infarction, heart failure, or stroke (NCT02587351)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Myocardial Infarction | Heart Failure | Stroke | Sudden Cardiac Death | |
| Metoprolol Succinate | 2 | 2 | 1 | 0 |
| Placebo | 1 | 3 | 1 | 1 |
Fibrinogen: assessed at screening/randomization and at conclusion of the study to determine if beta-blockade impacts levels of systemic inflammation that portend overall cardiac risk. (NCT02587351)
Timeframe: Baseline, 1 year
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Fibrinogen baseline | Fibrinogen Visit 336 | |
| Metoprolol Succinate | 384.8 | 392.5 |
| Placebo | 378.2 | 386.0 |
Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The Bodily Pain Scale includes 2 items assessing the intensity of pain and effect of pain on normal work, both inside and outside the house. Items are transformed to a score with a range of 0-100. (NCT02587351)
Timeframe: 1 year
| Intervention | Units on a scale (Median) | ||
|---|---|---|---|
| Baseline | Day 112 visit | Day 336 Visit | |
| Metoprolol Succinate | 67.5 | 67.5 | 57.5 |
| Placebo | 67.5 | 67.5 | 57.5 |
Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The Emotional Well-being Scale includes 5 items assessing emotional wellbeing. Items are transformed to a score with a range of 0-100. (NCT02587351)
Timeframe: 1 year
| Intervention | Units on a scale (Median) | ||
|---|---|---|---|
| Baseline | Day 112 visit | Day 336 Visit | |
| Metoprolol Succinate | 76.0 | 76.0 | 76.0 |
| Placebo | 72.0 | 72.0 | 72.0 |
Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The Energy/Fatigue Scale includes 4 items. Items are transformed to a score with a range of 0-100. (NCT02587351)
Timeframe: 1 year
| Intervention | Units on a scale (Median) | ||
|---|---|---|---|
| Baseline | Day 112 visit | Day 336 Visit | |
| Metoprolol Succinate | 50.0 | 50.0 | 50.0 |
| Placebo | 50.0 | 45.0 | 45.0 |
Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The General Health Scale includes 4 items assessing personal evaluations of health. Items are transformed to a score with a range of 0-100. (NCT02587351)
Timeframe: 1 year
| Intervention | Units on a scale (Median) | ||
|---|---|---|---|
| Baseline | Day 112 visit | Day 336 Visit | |
| Metoprolol Succinate | 40.0 | 40.0 | 40.0 |
| Placebo | 40.0 | 35.0 | 35.0 |
Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. 8 multi-item scales with higher score indicating better health state. The Physical Functioning scale is 10 items assessing the extent to which health limits physical activities such as self-care, walking, climbing stairs, bending lifting, and moderate and vigorous activities transformed to a score with a range of 0-100. (NCT02587351)
Timeframe: 1 year
| Intervention | Units on a scale (Median) | ||
|---|---|---|---|
| Baseline | Day 112 visit | Day 336 Visit | |
| Metoprolol Succinate | 30.0 | 30.0 | 30.0 |
| Placebo | 30.0 | 30.0 | 35.0 |
Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The Role Functioning - Emotional Scale includes 3 items assessing extent to which emotional problems interfere with work or other daily activities. Items are transformed to a score with a range of 0-100. (NCT02587351)
Timeframe: 1 year
| Intervention | Units on a scale (Median) | ||
|---|---|---|---|
| Baseline | Day 112 visit | Day 336 Visit | |
| Metoprolol Succinate | 100.0 | 66.7 | 66.7 |
| Placebo | 66.7 | 66.7 | 66.7 |
Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The Role Functioning - Physical Scale contains 4 items assessing the extent to which physical health interferes with work or other daily activities, including accomplished less than wanted, limitations in the kind of activities. Items are transformed to a score with a range of 0-100. (NCT02587351)
Timeframe: 1 year
| Intervention | Units on a scale (Median) | ||
|---|---|---|---|
| Baseline | Day 112 visit | Day 336 Visit | |
| Metoprolol Succinate | 25.0 | 25.0 | 12.5 |
| Placebo | 25.0 | 25.0 | 12.5 |
Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The Social Functioning Scale includes 2 items assessing extent to which physical health or emotional problems interfere with normal social activities. Items are transformed to a score with a range of 0-100. (NCT02587351)
Timeframe: 1 year
| Intervention | Units on a scale (Median) | ||
|---|---|---|---|
| Baseline | Day 112 visit | Day 336 Visit | |
| Metoprolol Succinate | 62.5 | 62.5 | 75.0 |
| Placebo | 62.5 | 62.5 | 62.5 |
1 review available for metoprolol and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Practical recommendations for the use of beta-blockers in chronic obstructive pulmonary disease.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Heart Failure; Humans; Metoprolol; Myocardial Isc | 2020 |
9 trials available for metoprolol and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Lung Function and the Risk of Exacerbation in the β-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease Trial.
Topics: Bronchodilator Agents; Forced Expiratory Volume; Humans; Lung; Metoprolol; Pulmonary Disease, Chroni | 2022 |
Association between P-pulmonale and respiratory morbidity in COPD: a secondary analysis of the BLOCK-COPD trial.
Topics: Adrenergic beta-Antagonists; Disease Progression; Humans; Metoprolol; Morbidity; Pulmonary Disease, | 2023 |
Metoprolol for the Prevention of Acute Exacerbations of COPD.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Disease Progression; Female; Forced | 2019 |
Beta-blockeRs tO patieNts with CHronIc Obstructive puLmonary diseasE (BRONCHIOLE) - Study protocol from a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Cardiovascular Diseases; Endpoint Determination; Female; Humans; Male; | 2020 |
Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study.
Topics: Adrenergic beta-1 Receptor Agonists; Aged; Bisoprolol; Carvedilol; Cause of Death; Comorbidity; Denm | 2018 |
[Efficacy and safety of bisoprololal in hypertensive patients with cardiovascular disease and chronic obstructive pulmonary disease].
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Antihypertensive Agents; Bisoprolol; Cardiovascular Di | 2014 |
β-Blockers for the prevention of acute exacerbations of chronic obstructive pulmonary disease (βLOCK COPD): a randomised controlled study protocol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Cause of Death; Disease Progression; Do | 2016 |
Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Chr | 2010 |
Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Bronchial Hyperreactivity; Bronc | 2005 |
16 other studies available for metoprolol and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Beta-blocker choice and exchangeability in patients with heart failure and chronic obstructive pulmonary disease: an Italian register-based cohort study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atrioventricular Block; Bisoprolol; Carvedilol | 2019 |
Beta-blocker Use in Moderate and Severe Chronic Obstructive Pulmonary Disease.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bisoprolol; Case-Control | 2019 |
Beta-Blockers in COPD - A Controversy Resolved?
Topics: Adrenergic beta-Antagonists; Humans; Metoprolol; Pulmonary Disease, Chronic Obstructive | 2019 |
Metoprolol is not effective for preventing acute exacerbations in COPD.
Topics: Humans; Metoprolol; Pulmonary Disease, Chronic Obstructive | 2020 |
Metoprolol Versus Carvedilol in Patients With Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes Mellitus, and Renal Failure.
Topics: Acute Disease; Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged | 2020 |
Metoprolol for the Prevention of Exacerbations of COPD.
Topics: Bronchodilator Agents; Humans; Metoprolol; Pulmonary Disease, Chronic Obstructive | 2020 |
Metoprolol for the Prevention of Exacerbations of COPD.
Topics: Bronchodilator Agents; Humans; Metoprolol; Pulmonary Disease, Chronic Obstructive | 2020 |
Metoprolol for the Prevention of Exacerbations of COPD.
Topics: Bronchodilator Agents; Humans; Metoprolol; Pulmonary Disease, Chronic Obstructive | 2020 |
Metoprolol for the Prevention of Exacerbations of COPD. Reply.
Topics: Bronchodilator Agents; Humans; Metoprolol; Pulmonary Disease, Chronic Obstructive | 2020 |
The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Chi-Square | 2017 |
Use of β2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adrenergic beta-Antag | 2019 |
Carvedilol, Bisoprolol, and Metoprolol Use in Patients With Coexistent Heart Failure and Chronic Obstructive Pulmonary Disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Con | 2016 |
Beta-blockers are safe in patients with chronic obstructive pulmonary disease, but only with caution.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Atenolol; Cardiovascular Diseases; Contraindi | 2008 |
Metoprolol, a beta-1 selective blocker, can be used safely in coronary artery disease patients with chronic obstructive pulmonary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Aged; Blood Pressure; Coronary | 2003 |
Hospitalization rates of generic metoprolol compared with the original beta-blocker in an epidemiological database study.
Topics: Adrenergic beta-Antagonists; Aged; Arrhythmias, Cardiac; Arthritis, Rheumatoid; Databases, Factual; | 2007 |
[Administration of cardioselective beta-adrenoblockers in patients with arterial hypertension and/or ischemic heart disease associated with bronchoobstructive syndrome].
Topics: Adrenergic beta-Antagonists; Asthma; Benzopyrans; Comorbidity; Drug Administration Schedule; Ethanol | 2007 |